menu
    • menu

    Company profile for Acepodia

    NEW Drugs in Dev.: 4
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    The mission of Acepodia, Inc. is to develop safe, effective, and affordable immunotherapeutic medicines targeting diseases with significant unmet medical needs, with our current primary focus in oncology. Our collaboration ranges from academies, hospitals to industries. Acepodia is committed to immunotherapeutic strategies against oncology – expanding our research, clinical development, and manufacturing capabilities. Acepod...
    The mission of Acepodia, Inc. is to develop safe, effective, and affordable immunotherapeutic medicines targeting diseases with significant unmet medical needs, with our current primary focus in oncology. Our collaboration ranges from academies, hospitals to industries. Acepodia is committed to immunotherapeutic strategies against oncology – expanding our research, clinical development, and manufacturing capabilities. Acepodia currently has a broad pipeline portfolio, each targeting a different type of cancer.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AcepodiaTaiwan Flag
    Country
    Country
    Taiwan
    Address
    Address
    Rm. 7, 17F., No.99, Sec. 1, Sintai 5th Rd., Sijhih Dist., New Taipei City 2217...
    Telephone
    Telephone
    +886-2-26976100
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.acepodia.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/acepodia/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Biocytogen, Acepodia Enhance Collaboration For BsAD2C Development
    Biocytogen, Acepodia Enhance Collaboration For BsAD2C Development

    09 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-09/biocytogen-and-acepodia-expand-collaboration-through-option-based-evaluation-framework-for-first-in

    PHARMIWEB
    09 Jan 2026
    Share Share
    Acepodia Presents AD2C Technology Data at AACR Meeting 2025
    Acepodia Presents AD2C Technology Data at AACR Meeting 2025

    21 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/acepodia-presents-preclinical-data-on-antibody-dual-drugs-conjugation-ad2c-technology-at-aacr-annual-meeting-2025-302433216.html

    PR NEWSWIRE
    21 Apr 2025
    Share Share
    Biocytogen And Acepodia To Advance Bispecific Antibody, ADCs
    Biocytogen And Acepodia To Advance Bispecific Antibody, ADCs

    07 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250107874851/en

    BUSINESSWIRE
    07 Jan 2025
    Share Share
    Acepodia Announces FDA Clearance in IgG4-Related Disease
    Acepodia Announces FDA Clearance in IgG4-Related Disease

    15 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/acepodia-announces-fda-clearance-of-investigational-new-drug-application-for-ace1831-in-igg4-related-disease-302306506.html

    PR NEWSWIRE
    15 Nov 2024
    Share Share
    Acepodia and Pfizer Collaborate to Advance Chemistry-Based Cell Therapies
    Acepodia and Pfizer Collaborate to Advance Chemistry-Based Cell Therapies

    03 Sep 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/acepodia-and-pfizer-ignite-click-together-advance-chemistry-based-cell-therapies

    FIERCE BIOTECH
    03 Sep 2024
    Share Share
    Acepodia Announces FDA Clearance of Investigational NDA for ACE2016
    Acepodia Announces FDA Clearance of Investigational NDA for ACE2016

    04 Feb 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/acepodia-announces-fda-clearance-of-investigational-new-drug-application-for-ace2016-a-first-in-class-allogeneic-anti-egfr-cell-therapy-302052466.html

    PR NEWSWIRE
    04 Feb 2024
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search